Xtandi reduced the risk of death by 34 percent in men with metastatic hormone sensitive prostate cancer in a Phase III study.
List view / Grid view
metastatic hormone-sensitive prostate cancer (mHSPC)
Xtandi™ (enzalutamide) was approved for metastatic hormone-sensitive prostate cancer after it reduced the risk of radiographic progression or death by 61 percent in a trial.
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.